INTEGRATING MEDICAL STRATEGY, VALUE AND ANALYTICS
Science and medicine are evolving at a rate never seen before with advances in genomics, gene editing technologies, innovative drug delivery, biomarker identification and testing and use of artificial intelligence. That is why our Medical division – operating under the group name of MEDiSTRAVA and including the medical agency ApotheCom – focuses on supporting late stage biotech and innovative pharmaceutical companies in bringing to market specialised medicines and technologies to the stakeholders who need them most.
MEDiSTRAVA works with medical, clinical, health economics and market access stakeholders to accelerate the availability and understanding of scientific, clinical and economic evidence for new treatments and health technologies. Core services include medical affairs strategy, operations and effectiveness evaluation, scientific strategy and medical communications, publications, medical education, market access, health economics and outcomes research and real-world evidence design and solutions.
In a record-breaking year for FDA drug approvals in 2018, MEDiSTRAVA supported launch preparedness for 11 out of 59 new approvals. The division’s client base includes large pharma and a broad spectrum of late-stage biotech companies spanning West Coast, US and Cambridge, Boston who are increasingly taking assets through to launch. Adding in 13 new client organisations, the Medical division has a rapidly expanding and diverse client base supported by growing teams in San Francisco and Boston as well as our global hubs in London, NYC and Philadelphia. This has led to an increased volume of consultancy projects drawing on the Group’s 20 years of experience in medical affairs strategy and operational excellence. In addition, new proprietary tools to enable fast access to medical information together with advanced analytics allows us to support the increasing requirements of industry and evaluate the effectiveness of approach – focusing on accelerating the speed at which new, innovative technologies and medicines are available to patients.